- Home
- BCRX vs TARS Comparison
BCRX vs TARS Comparison
Compare BCRX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- TARS
- Stock Information
- Founded
- BCRX 1986
- TARS 2016
- Country
- BCRX United States
- TARS United States
- Employees
- BCRX N/A
- TARS N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- TARS Medicinal Chemicals and Botanical Products
- Sector
- BCRX Health Care
- TARS Health Care
- Exchange
- BCRX Nasdaq
- TARS Nasdaq
- Market Cap
- BCRX 1.7B
- TARS 1.7B
- IPO Year
- BCRX 1994
- TARS 2020
- Fundamental
- Price
- BCRX $9.19
- TARS $40.80
- Analyst Decision
- BCRX Buy
- TARS Strong Buy
- Analyst Count
- BCRX 9
- TARS 7
- Target Price
- BCRX $16.89
- TARS $67.14
- AVG Volume (30 Days)
- BCRX 3.6M
- TARS 589.9K
- Earning Date
- BCRX 08-04-2025
- TARS 08-07-2025
- Dividend Yield
- BCRX N/A
- TARS N/A
- EPS Growth
- BCRX N/A
- TARS N/A
- EPS
- BCRX N/A
- TARS N/A
- Revenue
- BCRX $503,485,000.00
- TARS $233,674,000.00
- Revenue This Year
- BCRX $39.04
- TARS $122.94
- Revenue Next Year
- BCRX $13.26
- TARS $44.14
- P/E Ratio
- BCRX N/A
- TARS N/A
- Revenue Growth
- BCRX 41.67
- TARS 449.03
- 52 Week Low
- BCRX $6.02
- TARS $20.08
- 52 Week High
- BCRX $11.31
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- BCRX 34.12
- TARS 40.57
- Support Level
- BCRX $9.19
- TARS $39.33
- Resistance Level
- BCRX $10.07
- TARS $42.00
- Average True Range (ATR)
- BCRX 0.34
- TARS 1.73
- MACD
- BCRX -0.18
- TARS 0.05
- Stochastic Oscillator
- BCRX 8.10
- TARS 17.95
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.